Mattia Bonsignori

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
  2. pmc HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
  3. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
  4. pmc HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
  5. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
  6. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
  7. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013
  8. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
  9. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
  10. pmc Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 88:5165-70. 2014

Collaborators

Detail Information

Publications18

  1. pmc Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family
    Mattia Bonsignori
    Duke University Medical Center, Durham, North Carolina, USA
    J Virol 86:11521-32. 2012
    ..The polyclonality and low mutation frequency of these VH1 antibodies reveal fundamental differences in the regulation and maturation of these ADCC-mediating responses compared to VH1 bNAbs...
  2. pmc HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Trends Microbiol 20:532-9. 2012
    ..Strategies are being developed for the analysis of infection and vaccine candidate-induced antibodies, their gene usage, and their maturation pathways such that this information can be used to attempt to guide rational vaccine design...
  3. pmc Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    Mattia Bonsignori
    Duke Human Vaccine Institute, Durham, North Carolina, USA
    J Virol 86:4688-92. 2012
    ..These data provide proof of concept for an HIV-1 vaccine that aims to elicit bnAbs of multiple specificities...
  4. pmc HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
    Mattia Bonsignori
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 183:2708-17. 2009
    ..The inability to generate high titers of long-lived anti-envelope Abs is a major hurdle to overcome for the development of a successful HIV-1 vaccine...
  5. pmc Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    Mattia Bonsignori
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Virol 85:9998-10009. 2011
    ..Thus, E.A244, B.9021, and AE.CM243 Envs are three potential immunogen candidates for studies aimed at defining strategies to induce V2/V3 conformational epitope-specific antibodies...
  6. pmc Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2
    Hua Xin Liao
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA
    Immunity 38:176-86. 2013
    ..Variation may signal sites of HIV-1 envelope vulnerability, providing vaccine designers with new options...
  7. pmc Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses
    Justin Pollara
    Department of Surgery, Duke University Medical Center, P O Box 2926, Durham, NC 27710, USA
    Curr HIV Res 11:378-87. 2013
    ..Here we discuss the HIV-1 envelope epitopes targeted by ADCC antibodies in the context of the potential protective capacities of ADCC. ..
  8. pmc Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 87:7828-36. 2013
    ..Although capture of infectious HIV-1 correlated with other humoral immune responses, the extent of variation between these humoral responses and virion capture indicates that virion capture antibodies occupy unique immunological space. ..
  9. pmc Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
    Georgia D Tomaras
    Duke Human Vaccine Institute, and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 110:9019-24. 2013
    ..We show that monomeric Env-specific IgA, as part of postvaccination polyclonal antibody response, may modulate vaccine-induced immunity by diminishing ADCC effector function...
  10. pmc Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity
    Pinghuang Liu
    Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA
    J Virol 88:5165-70. 2014
    ..Infectious virion capture was additive with a mixture of antibodies, providing proof of concept for vaccine-induced antibodies that together have improved capacity to recognize infectious virions. ..
  11. pmc HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities
    Justin Pollara
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 88:7715-26. 2014
    ..This is a major step in understanding how these types of antibodies may have cooperatively contributed to reducing infection risk and should be considered in the context of prospective vaccine design...
  12. pmc Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
    S Munir Alam
    Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA
    J Virol 87:1554-68. 2013
    ..These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity...
  13. pmc Progress in HIV-1 vaccine development
    Barton F Haynes
    Duke Human Vaccine Institute, Durham, NC Department of Medicine, Duke University School of Medicine, Durham, NC Department of Immunology, Duke University School of Medicine, Durham, NC Electronic address
    J Allergy Clin Immunol 134:3-10; quiz 11. 2014
    ..This review summarizes what some of the scientific advances have been, what roadblocks still remain, and what the most promising approaches are for progress in design of successful HIV-1 vaccine candidates. ..
  14. pmc Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide
    S Moses Dennison
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA
    J Virol 88:9406-17. 2014
    ..However, the MAb 17B itself did not block Env-Galcer binding, suggesting that the C1 antibody-induced gp120 conformational changes resulted in alteration in a Galcer binding site distant from the CD4i 17B MAb binding site...
  15. pmc Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved
    Kevin Wiehe
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA Electronic address
    Immunity 41:909-18. 2014
    ..These data indicate that the HIV-1 K169-recognizing ED motif has persisted over the diversification between rhesus macaques and humans, suggesting an evolutionary advantage of this antibody recognition mode...
  16. pmc Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
    David C Montefiori
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Infect Dis 206:431-41. 2012
    ..No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials...
  17. pmc Polyreactivity and autoreactivity among HIV-1 antibodies
    Mengfei Liu
    School of Medicine, Duke University, Durham, North Carolina, USA
    J Virol 89:784-98. 2015
    ..Among these four bNAbs, avidity for UBE3A was correlated with neutralization breadth. Identification of UBE3A as a self-antigen recognized by CD4bs bNAbs offers a mechanism for the rarity of this bNAb class...
  18. pmc Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors
    S Munir Alam
    Duke Human Vaccine Institute and Departments of Medicine, Pathology, and Immunology, Duke University Medical Center, Durham, NC 27710
    Proc Natl Acad Sci U S A 110:18214-9. 2013
    ....